An osteopontin/CD44 immune checkpoint controls CD8(+) T cell activation and tumor immune evasion

Despite breakthroughs in immune checkpoint inhibitor (ICI) immunotherapy, not all human cancers respond to ICI immunotherapy and a large fraction of patients with the responsive types of cancers do not respond to current ICI immunotherapy. This clinical conundrum suggests that additional immune chec...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Invest
Hlavní autoři: Klement, John D., Paschall, Amy V., Redd, Priscilla S., Ibrahim, Mohammed L., Lu, Chunwan, Yang, Dafeng, Celis, Esteban, Abrams, Scott I., Ozato, Keiko, Liu, Kebin
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6264631/
https://ncbi.nlm.nih.gov/pubmed/30395540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI123360
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky